The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size
about
The diploid genome sequence of an individual humanObserving Huntington's Disease: the European Huntington's Disease Network's REGISTRYEMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington diseaseTransgenic animal models for study of the pathogenesis of Huntington's disease and therapyGenetics and neuropathology of Huntington's diseaseDisease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolismA universal mechanism ties genotype to phenotype in trinucleotide diseasesSystems biology of neurodegenerative diseasesCurrent Status of Huntington's Disease in Korea: A Nationwide Survey and National Registry AnalysisThe threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegansEvidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16.A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study.Genetic background modulates behavioral impairments in R6/2 mice and suggests a role for dominant genetic modifiers in Huntington’s disease pathogenesis.Self-paced timing detects and tracks change in prodromal Huntington disease.Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.Predicting Disease Onset from Mutation Status Using Proband and Relative Data with Applications to Huntington's Disease.Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases.Genetic analysis of the GRIK2 modifier effect in Huntington's disease.Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.Presentation and care of a family with Huntington disease in a resource-limited community.Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease.Huntington's disease: silencing a brutal killer.Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington diseaseQEEG Measures in Huntington's Disease: A Pilot Study.Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic miceExamination of Huntington's disease in a Chinese familyHistone deacetylase complexes promote trinucleotide repeat expansionsGenetic analysis of polymorphisms in the kalirin gene for association with age-at-onset in European Huntington disease patients.Trinucleotide repeats and haplotypes at the huntingtin locus in an Indian sample overlaps with European haplogroup a.Statistical evaluation of age-at-onset anticipation: a new test and evaluation of its behavior in realistic applications.Localization of sequence variations in PGC-1α influence their modifying effect in Huntington disease.Mutation in E1, the ubiquitin activating enzyme, reduces Drosophila lifespan and results in motor impairment.CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.Natural genetic variation determines susceptibility to aggregation or toxicity in a C. elegans model for polyglutamine disease.Molecular interaction between the chaperone Hsc70 and the N-terminal flank of huntingtin exon 1 modulates aggregationLate onset Huntington Disease: clinical and genetic characteristics of 34 casesTransgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.Indexing disease progression at study entry with individuals at-risk for Huntington disease
P2860
Q21090194-E4168DC6-6049-4637-888C-4FF2E7BB1D82Q24598264-8E8D209C-70B2-483B-9B97-C09847AEF8F2Q24630629-2CE643A5-90CA-419A-B091-8772BCB01C95Q26849677-3190F83E-A776-4DFB-A07D-DE43B37B95F9Q27023050-7AA393A4-809B-43F6-B8B9-E7F1C958EE27Q27309160-7EA4634D-9771-480C-9C68-EE54395A3171Q27339179-AC5CBDCD-B459-4CDC-BC4A-BD7A769E6F62Q28080741-0E7E6B8C-D9B9-4D29-B5A8-8D0F59B3DF57Q28652090-A4B30673-A319-45A9-B734-D515807C1BF9Q29619760-F5A3A8DE-02A6-4EB4-8CF1-CA148E4F80FCQ30445013-CD2E692D-22C3-48B4-88EF-829C92EE1A7EQ30448206-5DD309B8-B910-4521-896B-0F8907DCB090Q30467288-8F37EC77-9E05-4356-8325-26123CA6FD71Q30474980-4362E20C-9888-4B62-84B7-3048D2B6D069Q30501353-94B24AB0-C776-4672-B6BF-F43E4F1D71D6Q30597292-D0FDE57D-7A86-49D7-AAFA-1F6F7F19DC7EQ33181735-A98B6873-F2B1-4E84-AE0D-C7DB59ABC8D3Q33256755-411C61D7-1852-4D04-A9F5-C2D9CC5A2FEBQ33291745-115BA0F5-4ED0-4847-BFDD-48ADF43E644BQ33556293-1C91B0E4-E7CE-481F-A0E7-F9CC358252B7Q33573371-EF13545C-3F02-4728-9BB4-7C5671360307Q33586461-531C2A8E-3ABA-4492-A5F9-99312EE1B92CQ33644718-BA984113-CE32-4E41-AD06-059A5C7CC86EQ33734662-1A0AF966-358A-48BF-8032-4B430167DE00Q33931283-20C360E4-7489-4216-93F2-A4F04606E793Q34017941-C5DCBEA3-6C99-4D74-AE91-F6D4D66B9F4CQ34095823-6A6341E9-B0A7-492D-8E2B-84E1F5EA984BQ34169694-D08D267D-E7C7-4FD6-AE09-9277529C028AQ34312581-0EDD79CF-0E86-4E76-BF1B-2911A5D1AFCDQ34381607-EF44EFBD-3EEA-4B59-BF06-60A4F8DE4FF7Q34385343-AFAE5DA6-AA91-4300-9E0F-6F3765127F05Q34498391-FB5CF972-C4A0-4B35-AA25-3B3F0805D491Q34574992-927A54FB-4FB1-4BF2-BDFF-622EA31B4936Q34624785-09753611-6C18-4641-9010-1F2318F815EBQ34873673-62076F6D-7AD2-4024-968C-CCD12042AF92Q35002352-EF0B52F6-93BC-42EF-8D92-ADC205A2FF99Q35048841-E0EA4119-573F-4592-8094-32421068DB1FQ35117379-C4B19840-0391-41C7-B831-28B2197088F9Q35212462-75ADBAD4-72E0-40CC-B472-8BDEB8C770CFQ35216637-2B9970F8-144C-447E-8D24-05ED0C99B635
P2860
The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
The likelihood of being affect ...... r age, for a specific CAG size
@ast
The likelihood of being affect ...... r age, for a specific CAG size
@en
type
label
The likelihood of being affect ...... r age, for a specific CAG size
@ast
The likelihood of being affect ...... r age, for a specific CAG size
@en
prefLabel
The likelihood of being affect ...... r age, for a specific CAG size
@ast
The likelihood of being affect ...... r age, for a specific CAG size
@en
P2093
P2860
P1476
The likelihood of being affect ...... r age, for a specific CAG size
@en
P2093
Almqvist E
Brinkman RR
Theilmann J
P2860
P304
P407
P577
1997-05-01T00:00:00Z